| Theme |
Renal Osteodystrophy, Up-To-Date |
| Title |
Novel therapeutic strategies for ROD |
| Author |
Hiroaki Ogata |
Department of Internal Medicine, Showa University, Northern Yokohama Hospital |
| Author |
Chiaki Maeda |
Department of Internal Medicine, Showa University, Northern Yokohama Hospital |
| Author |
Kanji Shishido |
Department of Internal Medicine, Kawasaki Clinic |
| Author |
Eriko Kinugasa |
Department of Internal Medicine, Showa University, Northern Yokohama Hospital |
| [ Summary ] |
Renal osteodystrophy (ROD) leads to not only bone disorders, but also high morbidity and mortality of cardiovascular disease in patients receiving long-term dialysis therapy. It has been shown that conventional treatment, including calcium-based phosphate binder and active vitamin D ana logues, could not attain the novel therapeutic targets for ROD management, which have been proposed in the K/DOQI guidelines. Currently, in Japan, sevelamer hydrochloride is clinically available, as well as new vitamin D analogues. In this article, we review some new therapeutic strategies for the treatment of ROD. |